Your browser is no longer supported. Please, upgrade your browser.
AQST Aquestive Therapeutics, Inc. daily Stock Chart
AQST [NASD]
Aquestive Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.78 Insider Own5.90% Shs Outstand33.59M Perf Week5.35%
Market Cap177.79M Forward P/E- EPS next Y-1.76 Insider Trans-9.75% Shs Float29.57M Perf Month-39.95%
Income-49.90M PEG- EPS next Q-0.46 Inst Own55.30% Short Float6.35% Perf Quarter4.11%
Sales59.30M P/S3.00 EPS this Y11.80% Inst Trans0.03% Short Ratio1.66 Perf Half Y50.71%
Book/sh-0.64 P/B- EPS next Y-16.60% ROA-78.20% Target Price- Perf Year67.30%
Cash/sh0.76 P/C7.00 EPS next 5Y- ROE241.10% 52W Range1.41 - 10.00 Perf YTD-8.59%
Dividend- P/FCF- EPS past 5Y-36.50% ROI-106.20% 52W High-46.80% Beta-
Dividend %- Quick Ratio2.70 Sales past 5Y90.00% Gross Margin68.60% 52W Low277.30% ATR0.53
Employees232 Current Ratio3.00 Sales Q/Q95.50% Oper. Margin-66.20% RSI (14)41.71 Volatility7.01% 8.44%
OptionableYes Debt/Eq- EPS Q/Q91.50% Profit Margin-84.20% Rel Volume0.50 Prev Close5.38
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume1.13M Price5.32
Recom1.80 SMA20-2.68% SMA50-23.20% SMA2006.91% Volume560,972 Change-1.12%
Apr-22-19Initiated H.C. Wainwright Buy
Jan-03-19Initiated Lake Street Buy $14
Aug-20-18Initiated RBC Capital Mkts Outperform $23
Aug-20-18Initiated JMP Securities Mkt Outperform $29
Oct-19-20 07:21AM  
Oct-14-20 07:30AM  
Sep-30-20 11:00AM  
Sep-29-20 06:06PM  
Sep-28-20 04:25AM  
Sep-25-20 05:38PM  
08:51AM  
Sep-17-20 10:11AM  
Aug-20-20 08:11AM  
07:30AM  
Aug-18-20 11:06AM  
Aug-10-20 07:30AM  
Aug-05-20 06:31PM  
Aug-04-20 07:35PM  
04:01PM  
08:18AM  
Jul-28-20 04:15PM  
12:33PM  
Jul-15-20 07:57AM  
Jul-06-20 09:49AM  
Jun-29-20 07:00AM  
Jun-25-20 11:22AM  
Jun-16-20 08:00AM  
Jun-04-20 05:05PM  
May-28-20 09:42AM  
May-27-20 09:22AM  
May-22-20 07:10AM  
May-21-20 05:27PM  
May-20-20 11:30AM  
May-14-20 08:25AM  
May-12-20 12:00PM  
May-08-20 08:15AM  
May-07-20 02:00PM  
May-06-20 06:00PM  
May-05-20 04:05PM  
Apr-28-20 12:34PM  
Apr-26-20 07:51AM  
Apr-21-20 09:15AM  
Apr-15-20 08:50AM  
Apr-14-20 09:13AM  
Mar-17-20 07:00AM  
Mar-14-20 08:15AM  
Mar-13-20 10:23AM  
Mar-11-20 06:25PM  
04:30PM  
Mar-05-20 12:30PM  
Mar-03-20 03:00PM  
Feb-20-20 07:00AM  
Feb-10-20 07:00AM  
Feb-06-20 07:00AM  
Jan-29-20 12:30PM  
Jan-12-20 06:16PM  
Jan-10-20 06:30AM  
Dec-22-19 06:09PM  
Dec-17-19 05:31AM  
Dec-12-19 08:00PM  
Dec-11-19 07:21AM  
Dec-10-19 04:01PM  
Dec-09-19 10:04AM  
Dec-04-19 08:30AM  
Dec-03-19 07:59AM  
Dec-02-19 07:30AM  
Nov-29-19 10:29AM  
Nov-26-19 04:05PM  
11:27AM  
11:07AM  
Nov-25-19 08:56AM  
08:00AM  
Nov-24-19 04:19PM  
Nov-22-19 04:42PM  
Nov-14-19 01:31PM  
Nov-13-19 08:30AM  
Nov-11-19 09:00AM  
Nov-07-19 09:42AM  
Nov-05-19 06:35PM  
04:50PM  
Oct-30-19 10:33AM  
Oct-18-19 10:43AM  
Oct-16-19 07:06AM  
Oct-15-19 05:41PM  
Sep-30-19 07:00AM  
Sep-03-19 03:25PM  
Aug-30-19 06:00AM  
Aug-26-19 08:30AM  
Aug-06-19 08:05PM  
05:22PM  
04:28PM  
Jul-31-19 10:36AM  
Jul-29-19 11:45AM  
Jul-18-19 02:23PM  
Jul-17-19 01:38PM  
Jul-15-19 04:35PM  
Jun-07-19 08:30AM  
Jun-04-19 08:00AM  
May-13-19 08:00AM  
May-08-19 07:31AM  
07:00AM  
07:00AM  
May-07-19 07:00PM  
Apr-26-19 03:55PM  
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maxwell John T.SVP-Chief Financial OfficerAug 18Sale8.003,00024,000150,614Aug 19 08:55 AM
Kendall Keith JCEO and PresidentJun 30Option Exercise0.003330639,297Jul 02 04:00 PM
Schobel Alexander MarkChief Innovation/Tech OfficerJun 30Option Exercise0.003330912,886Jul 02 04:00 PM
Kendall Keith JCEO and PresidentJun 04Sale5.1150,000255,310638,964Jun 05 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMay 31Option Exercise0.0014,5720916,685Jun 02 05:14 PM
Kendall Keith JCEO and PresidentMay 31Option Exercise0.0014,5720695,456Jun 02 05:13 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMay 08Sale5.0040,000200,000902,113May 11 04:15 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 29Sale4.5040,000180,0001,022,113May 01 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 27Sale4.0040,000160,000942,113May 04 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerApr 14Sale3.7040,000148,000982,113May 04 04:05 PM
Schobel Alexander MarkChief Innovation/Tech OfficerMar 31Option Exercise0.0032901,062,210Apr 02 04:16 PM
Kendall Keith JCEO and PresidentMar 31Option Exercise0.003290680,983Apr 02 04:16 PM
BRAENDER LORI JSVP, General CounselMar 16Buy1.5414,00021,62425,000Mar 18 04:45 PM
Boyd Peter E.SVP-Bus. Process & Info. Tech.Mar 16Buy1.502,0003,00052,239Mar 18 04:45 PM
Kendall Keith JCEO and PresidentFeb 29Option Exercise0.0014,5720685,383Mar 03 07:37 PM
Schobel Alexander MarkChief Innovation/Tech OfficerFeb 29Option Exercise0.0014,57201,066,947Mar 03 07:38 PM
Schobel Alexander MarkChief Innovation/Tech OfficerDec 31Option Exercise0.0032901,044,494Jan 02 04:15 PM
Kendall Keith JCEO and PresidentDec 31Option Exercise0.003290662,985Jan 02 02:04 PM
Kendall Keith JCEO and PresidentNov 30Option Exercise0.0014,5720677,228Dec 02 04:56 PM
Schobel Alexander MarkChief Innovation/Tech OfficerNov 30Option Exercise0.0014,57201,058,737Dec 02 04:56 PM